Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Justet (Paris , France), S. Demagny (Paris , France), T. Boghanim (Paris , France), M. Jaillet (Paris , France), E. Marchal-Duval (Paris , France), A. Cazes (Paris , France), P. Mordant (Paris , France), Y. Castier (Paris , France), A. Mailleux (Paris , France), B. Crestani (Paris , France). Implication of FGFR4 and its ligands in Idiopathic Pulmonary Fibrosis. 4799

Member's Comments

No comment yet.

Related content which might interest you: FGFR4 has pro fibrotic properties in Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 FGF19, a potential innovative target in Idiopathic Pulmonary Fibrosis? Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019 Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Impact of depression on patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Regulation of WISP1 by profibrotic cytokines in pulmonary fibrosis Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014 Plasma derived-exosome microRNAs in Idiopathic Pulmonary Fibrosis of Anti-synthetase syndrome Disease patients Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 Impact of specific organic exposure on the prognosis in Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018